Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.16)
# 396
Out of 5,149 analysts
94
Total ratings
51.47%
Success rate
16.1%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $28.81 | +56.20% | 3 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $100 → $125 | $64.53 | +93.71% | 4 | Feb 25, 2026 | |
| ACLX Arcellx | Downgrades: In-Line | $115 | $114.05 | +0.83% | 2 | Feb 24, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $8.91 | +102.02% | 2 | Feb 24, 2026 | |
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $49.83 | -29.76% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $766.66 | +14.13% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $21.54 | +85.70% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $25.18 | +118.43% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $27.22 | +28.58% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $13.51 | +85.05% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.36 | +443.48% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $60.72 | +31.75% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $15.11 | +125.02% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $43.79 | +25.60% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $131.14 | +41.07% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $100.76 | +24.06% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $58.53 | +79.40% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $22.07 | +298.73% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $184.02 | +49.98% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.93 | +790.59% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $377.00 | -38.46% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $98.07 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $147.83 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.20 | -28.08% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.21 | +270.37% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.61 | +521.12% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.16 | - | 5 | Feb 14, 2018 |
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $28.81
Upside: +56.20%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $100 → $125
Current: $64.53
Upside: +93.71%
Arcellx
Feb 24, 2026
Downgrades: In-Line
Price Target: $115
Current: $114.05
Upside: +0.83%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $8.91
Upside: +102.02%
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $49.83
Upside: -29.76%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $766.66
Upside: +14.13%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $21.54
Upside: +85.70%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $25.18
Upside: +118.43%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $27.22
Upside: +28.58%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $13.51
Upside: +85.05%
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $7.36
Upside: +443.48%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $60.72
Upside: +31.75%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $15.11
Upside: +125.02%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $43.79
Upside: +25.60%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $131.14
Upside: +41.07%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $100.76
Upside: +24.06%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $58.53
Upside: +79.40%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $22.07
Upside: +298.73%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $184.02
Upside: +49.98%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.93
Upside: +790.59%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $377.00
Upside: -38.46%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $98.07
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $147.83
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.20
Upside: -28.08%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.21
Upside: +270.37%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.61
Upside: +521.12%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $13.16
Upside: -